Acute kidney injury: Clinical trials in AKI: is the end in sight?
- PMID: 27026352
- PMCID: PMC12940508
- DOI: 10.1038/nrneph.2016.35
Acute kidney injury: Clinical trials in AKI: is the end in sight?
Conflict of interest statement
Competing interests
K.D.L. has consulted for ZS Pharma, Achaogen, Chemocentryx, and Durect. She has received compensation for travel from the American Society of Nephrology. She is an Amgen stockholder. M.P. declares no competing interests.
Comment on
-
Candidate Surrogate End Points for ESRD after AKI.J Am Soc Nephrol. 2016 Sep;27(9):2851-9. doi: 10.1681/ASN.2015070829. Epub 2016 Feb 8. J Am Soc Nephrol. 2016. PMID: 26857682 Free PMC article.
References
-
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int, Suppl. 2012;2:1–138.
-
- Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, et al. Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol. 2012;7(5):844–50. - PubMed
-
- Okusa MD, Molitoris BA, Palevsky PM, Chinchilli VM, Liu KD, Cheung AK, et al. Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials. Clinical journal of the American Society of Nephrology : CJASN. 2012;7(5):851–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
